Related Experiment Video

Updated: Jul 13, 2026

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

Report on the ISBTC mini-symposium on biologic effects of targeted therapeutics

Michael B Atkins1, David Carbone, George Coukos

  • 1Beth Israel Deaconess Medical Center, Boston, MA, USA. Matkins@BIDMC.harvard.edu

Journal of Immunotherapy (Hagerstown, Md. : 1997)
|August 2, 2007
PubMed

Insights

This mini-symposium reviewed the biologic effects of cancer therapies, including monoclonal antibodies and targeted agents, on the immune system. It identified knowledge gaps and discussed strategies for future research and clinical applications.

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Biologic therapies, including standard and targeted treatments, have complex interactions with the immune system.
  • Understanding these interactions is crucial for optimizing cancer treatment strategies.

Purpose of the Study:

  • To review current knowledge on the biologic effects of cancer therapies on immunity.
  • To identify gaps in understanding and discuss methods for acquiring missing information.
  • To inform basic science, clinical trial design, and treatment strategies.

Main Methods:

  • A mini-symposium convened experts to discuss various therapeutic modalities and their immunologic impacts.
  • Key topics included monoclonal antibodies, antiangiogenic/targeted therapies, chemotherapy, tyrosine kinase inhibitors, and epigenetic modulators.
  • Discussions also covered the role of cell death in modulating immune responses.

Main Results:

  • The symposium highlighted the multifaceted impact of diverse cancer therapies on immune functions such as antigen presentation, adaptive immunity, and T-cell responses.
  • Specific agents like tyrosine kinase inhibitors and farnesyltransferase inhibitors were discussed concerning their effects on T-cell subsets and activation.
  • The influence of chemotherapy and novel agents on angiogenesis and immune modulation was also a key focus.

Conclusions:

  • A comprehensive understanding of therapy-induced immunomodulation is essential for rational drug development and clinical application.
  • Identifying knowledge gaps and defining optimal correlative studies are critical for advancing biologic cancer therapy.
  • Future research should focus on designing combination regimens and employing robust correlative studies in clinical investigations.

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Therapeutic Drug Monitoring: Overview and Classification01:16

Therapeutic Drug Monitoring: Overview and Classification

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...